Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797514 | 0.85 | ITGB3 (0.64) | ITGB3ITGA2BOPRD1HDAC8DPP4 | |
| SCHEMBL7797516 | 0.85 | ITGB3 (0.64) | ITGB3ITGA2BOPRD1HDAC8DPP4 | |
| SCHEMBL8377724 | 0.80 | ITGB3 (0.47) | ITGB3ITGA2BOPRD1HRH2HRH1 | |
| SCHEMBL8377726 | 0.80 | ITGB3 (0.47) | ITGB3ITGA2BOPRD1HRH2HRH1 | |
| SCHEMBL7363744 | 0.78 | OPRD1 (0.61) | OPRD1HDAC8DPP4SMYD3HRH2 | |
| SCHEMBL8643771 | 0.77 | ITGB3 (0.45) | ITGB3ITGA2BOPRD1 | |
| SCHEMBL8879394 | 0.76 | DPP4 (0.53) | ITGB3ITGA2BOPRD1DPP4 | |
| SCHEMBL8879407 | 0.76 | DPP4 (0.53) | ITGB3ITGA2BOPRD1DPP4 | |
| SCHEMBL8383078 | 0.76 | OPRD1 (0.49) | ITGB3ITGA2BOPRD1HDAC8DPP4 | |
| Hydrochloric Acid SCHEMBL6165142 | 0.75 | HDAC8 (0.61) | OPRD1HDAC8DPP4SMYD3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | ITGB3 169/4885ITGA2B 63/4885OPRD1 1473/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | ITGB3 169/4885ITGA2B 63/4885OPRD1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.